Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoplatin and Visudyne PDT for Pleural Malignancies
NCT02702700Phase 1Terminated
- Sponsor
- Lausanne University Hospital
- Start
- Jan 2016
- Primary completion
- Aug 2018
- Modality
- Nanoparticles, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lipoplatin and verteporfin in malignant pleural effusion (MPE), sponsored by Lausanne University Hospital. Primary endpoints: 30-day postoperative mortality, Feasibility at 30 days and 4 more. Started Jan 2016; status: terminated.
02
Drugs
lipoplatinverteporfin
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT02702700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702700.